Crispr effector system based multiplex diagnostics
US-2021108267-A1 · Apr 15, 2021 · US
US11851702B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11851702-B2 |
| Application number | US-202016894664-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 5, 2020 |
| Priority date | Mar 23, 2020 |
| Publication date | Dec 26, 2023 |
| Grant date | Dec 26, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Systems and methods for rapid diagnostics related to the use of isothermal amplification reagents for detection of microbial species, including coronavirus, and methods of use, are provided.
Opening claim text (preview).
What is claimed is: 1. A cartridge comprising at least a first and second ampoule, a lysis chamber, an amplification chamber, and a sample receiving chamber, wherein the first ampoule comprises DNA isolation solution capable of isolating a target RNA from a crude or unprocessed sample comprising a cell or virus containing the target RNA and the second ampoule comprises a loop-mediated isothermal amplification (LAMP) composition for detecting the presence of the target RNA in a sample, comprising optimized LAMP primers consisting of SEQ ID NOs: 61983-61988 and amplification reagents for single amplification and glycine or taurine, or a combination thereof for amplifying the target RNA in less than one hour. 2. The cartridge of claim 1 , configured to fit in a system comprising a heating means, an optic means, a means for releasing reagents on the cartridge, and a means for readout of assay result. 3. The cartridge of claim 1 , wherein the contents of the first ampoule and/or second ampoule are lyophilized. 4. A device designed to receive one or more cartridges of claim 2 and further comprising one or more motors connected to a plunger for rupturing of the first and second ampoule of the cartridge and configured within the device to align with the first and second ampoule of the inserted cartridge, a heating element configured to align with the amplification chamber of the inserted cartridge, an optical detector configured to align with the amplification chamber of the inserted cartridge, and a display. 5. The device of claim 4 , further comprising a graphical user interface for programming the device and/or readout of the results of the assay. 6. A system comprising a docking station and two or more devices of claim 5 , wherein the docking station is configured to receive the two or more devices. 7. The cartridge of claim 1 , wherein the second ampoule comprises isothermal amplification reagents and a CRISPR-Cas collateral detection system for amplifying and detecting a target RNA. 8. The cartridge of claim 7 , wherein the target RNA is a coronavirus. 9. The cartridge of claim 1 , wherein the DNA isolation solution and/or the lysis well comprises RNA binding beads. 10. The cartridge of claim 1 , wherein the DNA isolation solution comprises a protease. 11. The cartridge of claim 10 , wherein the protease is proteinase K. 12. The cartridge of claim 1 , wherein the amplification reagents comprise reverse transcriptase. 13. The cartridge of claim 1 , wherein the first ampoule comprises isolation solution in an amount to provide a ratio from 2:1 to 1:2 isolation solution:crude or unprocessed sample. 14. The cartridge of claim 1 , wherein the LAMP composition further comprises colorimetric or fluorescent detection reagents.
Nucleic acid amplification reactions · CPC title
with fluid transport, e.g. in multi-compartment structures · CPC title
characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces · CPC title
with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples · CPC title
RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.